{"id":4778,"date":"2018-02-22T13:37:54","date_gmt":"2018-02-22T13:37:54","guid":{"rendered":"http:\/\/www.library.sath.nhs.uk\/research\/?p=4778"},"modified":"2018-08-21T09:31:12","modified_gmt":"2018-08-21T08:31:12","slug":"an-audit-of-real-world-systemic-chemotherapy-in-breast-cancer-patients-over-the-age-of-70-in-one-u-k-cancer-centre-2017","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2018\/02\/22\/an-audit-of-real-world-systemic-chemotherapy-in-breast-cancer-patients-over-the-age-of-70-in-one-u-k-cancer-centre-2017\/","title":{"rendered":"An audit of 'real world' systemic chemotherapy in breast cancer patients over the age of 70 in one U.K. Cancer Centre (2018)"},"content":{"rendered":"<p><strong>Type of publication:<\/strong><br \/>\nConference abstract<\/p>\n<p><strong>Author(s):<\/strong><br \/>\n*Choudhary Y.; *Pettit L.; *Khanduri S.<\/p>\n<p><strong>Citation:<\/strong><br \/>\nEuropean Journal of Surgical Oncology; Mar 2018; vol. 44<\/p>\n<p><strong>Abstract:<\/strong><br \/>\nBackground: Breast cancer incidence among the over 70's is increasing. Trial data from this age group is not as extensive when compared with younger patients. Co-morbidities are common and may lead to poor tolerance of chemotherapy. Cytotoxic chemotherapy usage in patients over 70 was audited to record toxicity and tolerability.Method: Patients aged &gt;70 years, diagnosed with invasive breast cancer between 01\/01\/2015 and 31\/12\/2015 treated with cytotoxic chemotherapy at the Shrewsbury and Telford Hospital NHS Trust were identified from the Somerset database. Clinical information was obtained from an electronic portal. Data collected: demographics, performance status, tumour characteristics, ER\/PR and HER2 status, chemotherapy regimen, treatment intent, number of chemotherapy cycles planned, number given, toxicities, and hospital admissions. Data was collected on an excel database.Results: Thirty patients were identified, all female. 26 were between 71 and 75, 2 were between 76 and 80, 2 &gt; 80 years. 20 patients (67%) ER\/PR receptor positive. 15 (50%) HER2 positive. The majority 29 (97%) had a performance status of 0\/1. Cardiovascular co-morbidities were the most common (57% pre-existing cardiovascular disease). 25 (83%) were treated with adjuvant intent. 15 (50%) were admitted to hospital, 6 (20%) with neutropenic sepsis. 12 (40%) had dose reductions. 21 (70%) completed their planned number of cycles. Chemotherapy was discontinued in 7 (23%) due to toxicity and 1 patient remains on treatment at the time of this audit. There were no patient deaths within 30 days of commencing chemotherapy.Conclusion: Chemotherapy usage in the &gt;70's was associated with higher risk breast cancer. Despite good baseline performance status, 50% of patients required hospital admission and 27% discontinued treatment due to toxicity. The decision to use chemotherapy must also account for potential toxicities and impact on quality of life. Increased contact with health professionals including tele-consults and increased specialist nurse support, will help to predict and manage toxicity and reduce admissions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Conference abstract Author(s): *Choudhary Y.; *Pettit L.; *Khanduri S. Citation: European Journal of Surgical Oncology; Mar 2018; vol. 44 Abstract: Background: Breast cancer incidence among the over 70's is increasing. Trial data from this age group is<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2018\/02\/22\/an-audit-of-real-world-systemic-chemotherapy-in-breast-cancer-patients-over-the-age-of-70-in-one-u-k-cancer-centre-2017\/\">Read more <span class=\"screen-reader-text\">An audit of 'real world' systemic chemotherapy in breast cancer patients over the age of 70 in one U.K. Cancer Centre (2018)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[768,245,256],"class_list":["post-4778","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-768","tag-breast-cancer","tag-chemotherapy"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=4778"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4778\/revisions"}],"predecessor-version":[{"id":4963,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4778\/revisions\/4963"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=4778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=4778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=4778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}